Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics is positioned for success in the biopharmaceutical industry due to its innovative T-cell programming technologies and a strong clinical-stage pipeline with multiple treatments in development for various cancers. The company's financials are also showing improvement with a lower COGS in the first quarter and expected operating expense reductions due to a cost restructuring plan. The company's potential for earlier treatment and inclusion in NCCN guidelines, as well as its perceived safety and success in clinical trials, are positive indicators for future growth and success.

Bears say

Autolus Therapeutics is facing potential challenges with reimbursement and production capabilities for its CAR-T therapies, limiting the market potential of its flagship product Aucatzyl. Furthermore, the positive data from the frontline IST may not result in immediate market expansion due to changes in NCCN guidelines not expected until 2027. Combined, these factors suggest a potential struggle for Autolus in achieving significant revenue growth in the near future.

Autolus Therapeutics (AUTL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.